How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Yang Liu; Pan Zheng

doi:10.1016/j.it.2018.10.009

How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.

Authors

Yang Liu¹, Pan Zheng²

Affiliations

¹ Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland Baltimore School of Medicine, Baltimore, MD 21201, USA. Electronic address: yaliu@ihv.umaryland.edu.
² Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland Baltimore School of Medicine, Baltimore, MD 21201, USA. Electronic address: pzheng@ihv.umaryland.edu.

Abstract

Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Monoclonal / immunology*
Antibodies, Monoclonal / therapeutic use
CTLA-4 Antigen / antagonists & inhibitors
CTLA-4 Antigen / immunology*
Humans
Neoplasms / drug therapy
Neoplasms / immunology*

Substances

Antibodies, Monoclonal
CTLA-4 Antigen

Abstract

Publication types

MeSH terms

Substances

Grants and funding